CytomX Therapeutics updates business, announces 2023 relationship with Moderna

CytomX Therapeutics (CTMX) announced its 2023 company priorities and provided a pipeline update which included anticipated milestones for 2023, recent progress and achievements in its wholly owned and collaboration pipeline, and a data update for the Phase 2, CX-2029 cohort expansion study. The company will host a call with investors to review the CX-2029 cohort expansion study data and potential key pipeline events for 2023. "For CX-2029 specifically, we have pushed the boundaries of biologics localization with our Probody technology to create a therapeutic window for the previously undruggable target, CD71. The full CX-2029 Phase 2 cohort expansion data continues to demonstrate encouraging clinical activity in unselected, heavily pre-treated patients with tumors of squamous histology and we look forward to working with our partner AbbVie to determine the next steps for this program," continued Dr. McCarthy. "We also start 2023 with an exciting new collaboration with Moderna (MRNA) that combines the power of our respective technologies to break new ground in oncology and other areas of unmet medical need. This latest alliance comes just weeks after our announcement of a major new collaboration with Regeneron (REGN). These collaborations underscore CytomX’s innovation and leadership and further strengthen our organizational foundation as we build for the future. Looking further out into 2023, we expect to make meaningful progress with AbbVie and BMS, to continue Phase 1 investigation of our first T-cell engaging therapy CX-904 and to file INDs for two new wholly owned programs," continued Dr. McCarthy.